Hypertension

Long-term cardiometabolic health in people born after assisted reproductive technology: a multi-cohort analysis

Eur Heart JPublished Multi-cohort analysis with meta-analysis of population-based birth cohorts

Authors' conclusion

These findings of small and statistically non-significant differences in offspring cardiometabolic outcomes should reassure people receiving ART.

Study context

Population
Offspring in population-based birth cohorts; mean age 13 months to 27.4 years (<10 years in 11/14 cohorts)
Participants
35,938 offspring14 cohorts
Comparison
ART conception vs natural conception
  • ARTn = 654
Outcome
Differences in SBP, DBP, HR, lipids and hyperglycaemic/insulin resistance markers
Methodological details14 population-based birth cohorts, Europe, Australia and Singapore, trajectory modelling of 4 cohorts with repeated measures
  • 14 population-based birth cohorts
  • Europe, Australia and Singapore
  • Trajectory modelling of 4 cohorts with repeated measures

Pooled result

As reported in the abstract

Cardiometabolic outcomes (ART minus NC)
ART vs NCDifference, mmHg (95% CI)
SBP
−0.53(−1.59 to 0.53)
DBP
−0.24(−0.83 to 0.35)
ART vs NCDifference, beat/min (95% CI)
HR
0.02(−0.91 to 0.94)
ART vs NCDifference, % (95% CI)
Total cholesterol
2.59(0.10–5.07)
HDL cholesterol
4.16(2.52–5.81)
LDL cholesterol
4.95(0.47–9.43)

Further pooled results

Trajectories of cardiometabolic outcomes from 2 to 26 years (4 cohorts)

ART associated with lower predicted SBP/diastolic blood pressure (DBP) in childhood (statistically significant)
Subtle trajectories to higher SBP and triglycerides (TG) in young adulthood
Most differences not statistically significant
  • 17 244 (244 ART) births

Original publication

Long-term cardiometabolic health in people born after assisted reproductive technology: a multi-cohort analysis. Eur Heart J. Published 6 February 2023. doi:10.1093/eurheartj/ehac726

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.